Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
10+ Emerging Markets, Japan & ANZ Transition in Final Phase Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. […]
